Larotrectinib indications, dosage, adverse reactions, efficacy and price, etc.

Larotinib is a new type of anti-cancer drug that belongs to the category of targeted therapy. Its main function is to block the growth and division of cancer cells by inhibiting the abnormal TRK protein activity caused by TRK (neuroprimitive ectodermal tumor) gene fusion. The following is a comprehensive introduction to larotrectinib, including detailed information on indications, dosage and usage, adverse reactions, efficacy, and price.

1. Indications:

The main indications for larotrectinib include:

Children's Soft Tissue Sarcoma: Larotrectinib is approved for the treatment of pediatric soft tissue sarcoma patients with TRK gene fusions.

AdultsTRKgene fusion-positive solid tumors: For adults with TRKgene fusion-positive solid tumors, larotrectinib treatment can also be considered.

2. Dosage and usage:

Oral administration: Larotinib is usually taken as an oral medication. Patients take it orally according to the prescribed dosage and usage according to the doctor's prescription, usually twice daily.

Individualized treatment: The dosage and usage will be determined according to the patient's specific situation, disease characteristics and doctor's recommendations. Genetic testing is required before treatment to determine whether the patient has TRK gene fusion.

3. Adverse reactions:

The use of larotrectinib may cause some adverse reactions, common ones include but are not limited to:

Fatigue: Patients may feel tired and weak.

Headache: The occurrence of headache symptoms.

Nausea and Vomiting: Patients may experience uncomfortable feelings of nausea and vomiting.

Elevated liver enzymes: Abnormal liver function may occur in some patients.

It should be noted that different patients respond differently to drugs, and the degree and frequency of adverse reactions may vary from individual to individual.

4. Effectiveness:

Children's soft tissue sarcoma: For children with soft tissue sarcoma, clinical trial results show that larotrectinib can cause tumor shrinkage or stabilization and achieve significant therapeutic effects.

Adult solid tumors: In adult patients with solid tumors positive for TRK gene fusion, larotrectinib also showed significant efficacy, improving the patient's survival and quality of life.

5. Price:

Larotrectinib has been launched in China and has not yet been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in hospitals. For specific conditions, it is recommended to consult the local hospital pharmacy. In foreign markets, larotinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions of generic drugs, and the price is around two to three thousand. It is worth noting that the ingredients of original drugs and generic drugs are basically the same.

Larotinib, as a targeted anti-cancer drug, has achieved significant efficacy in patients with TRK gene fusion-positive tumors. However, patients should fully understand the indications, dosage and usage, adverse reactions, price and other information of the drug before use, and conduct individualized treatment planning under the guidance of a doctor. This helps ensure patients receive the best possible treatment results while minimizing possible adverse effects and risks.